However, the development of a noninvasive, routine detection of tumor hypoxia to identify patients in need of more aggressive therapy is needed. Noninvasive methods such as magnetic resonance spectroscopy [5] and imaging of radiolabeled compounds that are selectively retained in regions of hypoxia have been studied.
Detection of tumor hypoxia by a radionuclide imaging technique was first proposed by Chapman et al, who used radiolabeled 2-nitroimidazoles [6] . I-123 iodoazomycin arabinoside (IAZA) accumulated selectively in regions of tumor hypoxia [11] . Tc-99m-labeled ligands containing 2-nitroimidazole, including BMS 181321, and BRU59-21, displayed selectivity for tissues with hypoxia [12, 13] . Butyleneamine oxime (BnAO, HL91) is another Tc-99m complex and has shown even greater selectivity for hypoxia in tumor hypoxia [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] , ischemic myocardium [25] [26] [27] [28] [29] and cerebral ischemia [30] . In assessing treatment responses, a highly significant correlation was found between tumor uptake of HL91 and antitumor response to antivascular agents [18] . The mechanism of HL91 localization is not well understood. It was reported that the intrinsic properties of Tc-99m complexes are predominantly responsible for the selectivity for regions with hypoxia [16] .
Animal tumor models of a human lung cancer cell line (A549) and a murine lung cancer cell line (LL2) have been established. Both of these tumor models are known to contain hypoxic cells. HL91 uptake was compared between these two species in vitro and in vivo. The aim of this study was to determine whether HL91 identifies the presence of hypoxic cells in vitro and hypoxic tissues in vivo, and to measure the uptake of HL91 by imaging tumor hypoxia.
MATERIALS AND METHODS

Radiolabeled tracer
Lyophilized HL91 kits were prepared by the Institute of Nuclear Energy Research, Lungtan, Taiwan. Each HL91 kit contained 200 μg of HL91 ligand, 20 μg of stannous chloride dihydrate, 40 μg of methylene diphosphonic acid and buffer salts, in a 10 mL glass vial sealed under nitrogen atmosphere. Tc-99m-HL91 was prepared by reconstitution of an HL91 kit into 4.5 mL of a solution containing 900 MBq (24.3 mCi) of Tc-99msodium pertechnetate in accordance with the manufacturer's instructions. The radiochemical purity determined by thin layer chromatography was typically > 98%.
Uptake of Tc-99m HL91 into cells
The apparatus and procedures for the in vitro experiments are based on methods previously described [19] . Viability of cells was measured with a hemocytometer based on trypan blue exclusion. A549 and LL 2 cancer cells (1.2 × 10 6 cells/mL; American Type Culture Collection, Manassas, VA, USA) were separately cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with gentamicin (50 μg/mL), 2 mm L-glutamine, and 10% heat-inactivated fetal bovine serum at 37°C in 5% CO 2 . A continual flow of warmed, humidified gas (20% O 2 , 5% CO 2, 75% N 2 [normoxia], or 1% O 2 , 5% CO 2 , 94% N 2 [hypoxia]) was passed over the cells. pO 2 values were monitored by an oxygen analyzer within an automated value system (Pro-Ox, BioSpherix Ltd., Redfield, NY, USA). After equilibration of the humidified gas for 24 hours, 7.4 MBq HL91 was added to the cells. At 0.5, 1, 2, 3 and 4 hours after incubation with HL91, the media were removed. Cells were washed with phosphatebuffered saline (PBS). Cell suspensions were then centrifuged at 400g for 5 minutes, followed by aspiration of the supernatant. Radioactivity in the cell pellets was measured with a gamma counter (Cobra II, Packard Instrument Company, Meriden, CT, USA). Wells containing the culture medium without cells were similarly treated to assess absorbance of nonspecific radioactivity by the tubes. Experiments were performed twice to confirm the reproducibility of the results. The percentage uptake of the tracer into the cells was calculated.
Animal tumor models and biodistribution studies
All animal experiments were conducted in compliance with the Guidelines for the Care and Use of Research Animals established by National Cheng-Kung University's Animal Studies Committee. Severe combined immune deficiency (SCID) mice and C57BL/ 6NCrj (B6) mice were implanted subcutaneously into the right hind leg with A549 or LL2 cells (5 × 10 5 cells/mL). A total of 204 mice were grouped into A549 tumors (n = 66), LL2 tumors (n = 66), SCID controls (n = 36) or B6 controls (n = 36). HL91 (7.4 MBq) was injected into the tail vein and the animals were killed at 0.5, 1, 2, 3 or 4 hours post-injection. Selected tissues and organs were harvested and weighed, and the radioactivity counted on a gamma counter. The percentage injected dose per gram (%ID/g) for each tissue was calculated.
Tumor oxygenation was chemically reduced by hydralazine [19, 24] . Hydralazine (5 mg/kg) dissolved in 0.1 mL of saline was intraperitoneally administered 30 minutes prior to tracer injection. PBS-treated mice were injected with 0.1 mL of PBS. Each group consisted of six mice. Selected tissues and organs were removed from the animals at 2 and 4 hours post administration of HL91 (7.4 MBq). The %ID/g of each tissue was acquired.
Scintigraphic examination and image analysis
All six groups included SCID controls, B6 controls, PBS-treated A549 tumors, PBS-treated LL2 tumors, hydralazine-treated A549 tumors, and hydralazinetreated LL2 tumors (n = 6/group). Scintigraphic images were obtained at 0.5, 1, 2 and 4 hours after HL91 (37 MBq; 1 mCi) injection and were acquired with a gamma camera (Diacam, Siemens, Hoffman Estates, IN, USA) equipped with a low energy, high-resolution collimator. Tumor hypoxia was quantified by methods for defining regions of interest (ROI). The reference tissue was selected in the contralateral hind leg of the same mice. Tumor uptake ratios [ROI tumor/(ROI tumor + ROI contralateral)] were calculated.
Autoradiography and H&E staining
Animals bearing A549 and LL2 tumors were injected with 37 MBq (1 mCi) HL91 through the caudal vein and killed 2 hours after the injection. Tumors were removed and immediately frozen with liquid nitrogen. The frozen tumors were then embedded with O.C.T compound (Miles Inc., Elkhart, IN, USA) and cut into 10-μm-thick sections with a cryomicrotome (Bright OTF, Bright Instrument Company Ltd., Huntingdon, England). Frozen sections were applied to a phosphor imaging plate and exposed overnight. The distribution of radioactivity was estimated qualitatively by comparing the degree of darkening on each phosphor Imager (FLA5000, Fuji Photo Film Co., Tokyo, Japan). Darker gray levels represent greater concentrations of radioactivity. The other continuous sections that were mounted on clean slides were stained with hematoxylin and eosin (H&E) and examined under a light microscope.
Statistical analysis
Results are expressed as mean ± standard deviation. Statistical comparisons were done using Student's t test, assuming a significance level of 0.05.
RESULTS
Uptake of Tc-99m HL91 into cells
Hypoxic conditions significantly increased HL91 uptake into cells compared with normoxic conditions in both A549 ( Figure 1A ) and LL2 cells ( Figure 1B) . In A549 cells, HL91 uptake was increased by approximately 4-9-fold by hypoxia compared with normoxia ( Figure 1A ). Hypoxia had a greater effect in LL2 cells, increasing HL91 uptake by 10-16-fold ( Figure 1B) . 
Animal biodistribution studies
The biodistribution of HL91 in SCID controls (Table 1) was determined at 0.5, 1, 2, 3 and 4 hours after HL-91 injection. The liver retained the highest concentrations of HL-91 (range, 8.75 ± 2.67 to 9.13 ± 2.91 %ID/g). The lowest concentration was in the brain (range, 0.07 ± 0.01 to 0.08 ± 0.01 %ID/g). Intermediate levels were found in the bowel, stomach, spleen, kidney, lung, heart, bone and muscle. A similar biodistribution of HL91 was seen in normal B6 mice ( Table 2) . For mice bearing A549 tumors (Table 3 ) and LL2 tumors (Table 4) , the results of the biodistribution study showed that the liver had the highest concentrations and the brain the lowest. The intermediate levels in bowel, stomach, spleen, kidney, lung, heart, bone and muscle are shown. There was little apparent difference in the biodistribution between nontumor and tumor-bearing mice.
The presence of hydralazine significantly affected HL biodistribution within A549 tumors ( Table 5 ). Hydralazine resulted in selective and statistically significant increases in HL91 uptake. There was no statistically significant change in retention of HL91 in normal tissues after hydralazine injection, with the exception of a 59% increment at 2 hours and a 28% increment at 4 hours in the liver after administration of hydralazine. There were similar findings for the biodistribution in LL2 tumors ( Figure 2 shows scintigraphic images of normal SCID (Figure 2A ) and B6 mice ( Figure 2C ). There was an apparent accumulation of the radiotracer over the abdomen. In all of the mice bearing tumors, HL91 was retained in the tumors over the course of imaging up to 4 hours. Accumulation of the tracer in A549 ( Figure 3 ) and LL2 ( Figure 4 ) tumors was markedly increased in hydralazine-treated mice compared with PBS-treated mice. When HL91 uptake was compared using ROIs placed on scintigrams between hydralazine-and PBS-treated mice, A549 tumor uptake was increased by 3.75%, 7.41%, 10.98% and 13.58% relative to that of PBS-treated mice at 0.5, 1, 2 and 4 hours, respectively. Similarly, LL2 tumor accumulation of HL91 was increased by 13.34%, 14.82%, 31.06% and 29.08% at 0.5, 1, 2 and 4 hours, respectively ( Figure 5 ).
Scintigraphic examination and image analysis
Autoradiography and HE staining
The autoradiograms obtained from tumor samples revealed the highest apparent accumulation of radioactivity in the periphery of the A549 ( Figure 6A ) and LL2 tumors ( Figure 6D ). The regions with low HL91 uptake corresponded to histologically necrotic areas, as shown by H&E staining (Figures 6D and 6F) . The fused images ( Figures 6B and 6E ) from the autoradiography and H&E staining provided clear visual evidence for the preferential uptake of HL91 in the border zone.
DISCUSSION
Our study has revealed that HL91 shows good selectivity for hypoxic regions in vitro and in vivo. The percentage uptake of HL91 into A549 and LL2 cells in vitro was significantly increased under hypoxic conditions compared with normoxic conditions throughout the 4-hour study (Figure 1 ). There was no significant difference between human lung cancer cells and murine lung cancer cells. Hydralazine, which belongs to the antihypertensive class of medicines, has been shown to cause decreased blood flow to tumors that results in decreased oxygen concentrations within the implanted tumors [19, 24] . Therefore, hydralazine was used to chemically reduce tumor oxygenation. Tables 5 and 6 revealed that hydralazine-treated mice had greater HL91 uptake compared with PBS-treated mice for both A549 and LL2 tumors. Our findings are consistent with those of Kinuya et al [19] . No significant difference between A549 and LL2 tumors was found, but there was a significant difference between hydralazine-treated and PBS-treated tumors. All scintigrams of normal mice ( Figure 2 ) and of mice bearing tumors (Figures 3 and 4 ) showed high levels of radioactivity accumulation in the abdomen. According to the biodistribution results (Tables 1-6), abdominal uptake was mostly secondary to the radiotracer accumulation over the liver and bilateral kidneys. Little radioactivity was identified in the brain, lung, bone or muscle (Figures 2-4) . Visually, the hydralazine-treated mice showed higher tumor uptake of HL91 than did PBS-treated mice (Figures 3-5 ).
Both autoradiograms and H&E staining of tumor sections ( Figure 6 ) indicated low uptake of HL91 in necrotic areas and enhanced tracer uptake in the border zone, suggesting that this is a hypoxic region. Our results showed that HL91 uptake was lower in necrotic areas than in viable regions; hence, HL91 can distinguish oxidation status in tumor tissues. This result is consistent with the findings that HL91 was observed in the hypoxic zone [14] .
Our results show that HL91 imaging can noninvasively visualize and quantify tumor hypoxia in individual tumors. For both in vitro and in vivo evaluations, there was a several-fold higher accumulation of HL91 in tumor hypoxia. Our data suggest that HL91 imaging is feasible and provides adequate image quality. Future studies will address the use of this hypoxia imaging agent not only to clinically assess tumor hypoxia, but also to monitor the effectiveness of various strategies known to overcome hypoxia. Additional studies are now needed to determine whether assessment of tumor hypoxia with HL91 provides information about tumor behavior that cannot be obtained with conventional prognostic indicators.
Our autoradiographic data clearly support our in vitro results, biodistribution and scintigraphy. These results confirm the selectivity of HL91 for hypoxic tissues. Moreover, HL91 imaging can noninvasively visualize and semi-quantify the extent and spatial distribution of tumor hypoxia for individual tumors in living mice. Our data indicate the usefulness of this tracer as a hypoxia imaging agent. 
